These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 12939459)

  • 1. Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors.
    Frolov A; Chahwan S; Ochs M; Arnoletti JP; Pan ZZ; Favorova O; Fletcher J; von Mehren M; Eisenberg B; Godwin AK
    Mol Cancer Ther; 2003 Aug; 2(8):699-709. PubMed ID: 12939459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development.
    Demetri GD
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1115-24. PubMed ID: 12512386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal stromal tumors: overview of pathologic features, molecular biology, and therapy with imatinib mesylate.
    Koh JS; Trent J; Chen L; El-Naggar A; Hunt K; Pollock R; Zhang W
    Histol Histopathol; 2004 Apr; 19(2):565-74. PubMed ID: 15024716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects.
    Borg C; Terme M; Taïeb J; Ménard C; Flament C; Robert C; Maruyama K; Wakasugi H; Angevin E; Thielemans K; Le Cesne A; Chung-Scott V; Lazar V; Tchou I; Crépineau F; Lemoine F; Bernard J; Fletcher JA; Turhan A; Blay JY; Spatz A; Emile JF; Heinrich MC; Mécheri S; Tursz T; Zitvogel L
    J Clin Invest; 2004 Aug; 114(3):379-88. PubMed ID: 15286804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
    Demetri GD
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors.
    Chen H; Isozaki K; Kinoshita K; Ohashi A; Shinomura Y; Matsuzawa Y; Kitamura Y; Hirota S
    Int J Cancer; 2003 May; 105(1):130-5. PubMed ID: 12672043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT.
    Bauer S; Corless CL; Heinrich MC; Dirsch O; Antoch G; Kanja J; Seeber S; Schütte J
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):261-5. PubMed ID: 12655446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms.
    Tarn C; Skorobogatko YV; Taguchi T; Eisenberg B; von Mehren M; Godwin AK
    Cancer Res; 2006 May; 66(10):5477-86. PubMed ID: 16707477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Imatinib--a breakthrough in the treatment of gastrointestinal stromal tumors (GIST)].
    Larsen JB
    Ugeskr Laeger; 2003 Sep; 165(37):3503-7. PubMed ID: 14531349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biology of gastrointestinal stromal tumors: KIT mutations and beyond.
    Duensing A; Heinrich MC; Fletcher CD; Fletcher JA
    Cancer Invest; 2004; 22(1):106-16. PubMed ID: 15069768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
    Cohen NA; Zeng S; Seifert AM; Kim TS; Sorenson EC; Greer JB; Beckman MJ; Santamaria-Barria JA; Crawley MH; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Cancer Res; 2015 May; 75(10):2061-70. PubMed ID: 25836719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review.
    Miettinen M; El-Rifai W; H L Sobin L; Lasota J
    Hum Pathol; 2002 May; 33(5):478-83. PubMed ID: 12094372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes.
    Burger H; den Bakker MA; Kros JM; van Tol H; de Bruin AM; Oosterhuis W; van den Ingh HF; van der Harst E; de Schipper HP; Wiemer EA; Nooter K
    Cancer Biol Ther; 2005 Nov; 4(11):1270-4. PubMed ID: 16294026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?
    Scaife CL; Hunt KK; Patel SR; Benjamin RS; Burgess MA; Chen LL; Trent J; Raymond AK; Cormier JN; Pisters PW; Pollock RE; Feig BW
    Am J Surg; 2003 Dec; 186(6):665-9. PubMed ID: 14672776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate.
    Liu Y; Tseng M; Perdreau SA; Rossi F; Antonescu C; Besmer P; Fletcher JA; Duensing S; Duensing A
    Cancer Res; 2007 Mar; 67(6):2685-92. PubMed ID: 17363589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate: a molecularly targeted therapy for gastrointestinal stromal tumors.
    Eisenberg BL
    Oncology (Williston Park); 2003 Nov; 17(11):1615-20; discussion 1620, 1623, 1626 passim. PubMed ID: 14682111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro.
    Dziba JM; Ain KB
    J Clin Endocrinol Metab; 2004 May; 89(5):2127-35. PubMed ID: 15126530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.